Enzymatica AB (publ) (ENZY.ST)
SEK 3.45
(1.47%)
SEK 3.45
(1.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -48.06 Million SEK | 24.9% |
| 2022 | -68.21 Million SEK | -50.77% |
| 2021 | -45.24 Million SEK | -275.12% |
| 2020 | -12.06 Million SEK | 71.05% |
| 2019 | -41.66 Million SEK | -2.66% |
| 2018 | -40.58 Million SEK | -34.33% |
| 2017 | -30.21 Million SEK | 34.58% |
| 2016 | -46.17 Million SEK | -13.97% |
| 2015 | -40.51 Million SEK | -24.03% |
| 2014 | -32.66 Million SEK | -101.54% |
| 2013 | -16.2 Million SEK | -111.3% |
| 2012 | -7.67 Million SEK | -55.95% |
| 2011 | -4.91 Million SEK | 0.0% |
| 2009 | -74.92 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -18.4 Million SEK | -14.11% |
| 2024 Q2 | -13.42 Million SEK | 26.53% |
| 2023 Q3 | -8.74 Million SEK | 21.58% |
| 2023 Q4 | -16.12 Million SEK | -84.33% |
| 2023 FY | -51.23 Million SEK | 24.9% |
| 2023 Q1 | -14.38 Million SEK | 33.34% |
| 2023 Q2 | -11.15 Million SEK | 22.43% |
| 2022 Q3 | -12.61 Million SEK | 19.74% |
| 2022 Q4 | -21.57 Million SEK | -71.06% |
| 2022 FY | -68.21 Million SEK | -50.77% |
| 2022 Q1 | -18.14 Million SEK | -72.2% |
| 2022 Q2 | -15.71 Million SEK | 13.41% |
| 2021 Q2 | -20 Million SEK | -130.65% |
| 2021 Q4 | -10.53 Million SEK | -74.9% |
| 2021 FY | -45.24 Million SEK | -275.12% |
| 2021 Q1 | -8.67 Million SEK | -584.1% |
| 2021 Q3 | -6.02 Million SEK | 69.89% |
| 2020 Q1 | 220 Thousand SEK | 103.12% |
| 2020 Q4 | 1.79 Million SEK | 181.98% |
| 2020 Q3 | -2.18 Million SEK | 81.61% |
| 2020 Q2 | -11.88 Million SEK | -5503.64% |
| 2020 FY | -12.06 Million SEK | 71.05% |
| 2019 FY | -41.66 Million SEK | -2.66% |
| 2019 Q4 | -7.04 Million SEK | 1.15% |
| 2019 Q2 | -15.59 Million SEK | -31.16% |
| 2019 Q1 | -11.89 Million SEK | -75.41% |
| 2019 Q3 | -7.12 Million SEK | 54.3% |
| 2018 Q4 | -6.77 Million SEK | 26.11% |
| 2018 FY | -40.58 Million SEK | -34.33% |
| 2018 Q3 | -9.17 Million SEK | 38.91% |
| 2018 Q2 | -15.01 Million SEK | -56.33% |
| 2018 Q1 | -9.6 Million SEK | -105.37% |
| 2017 FY | -30.21 Million SEK | 34.58% |
| 2017 Q4 | -4.67 Million SEK | -108.28% |
| 2017 Q1 | -11.47 Million SEK | 38.07% |
| 2017 Q2 | -11.8 Million SEK | -2.89% |
| 2017 Q3 | -2.24 Million SEK | 80.98% |
| 2016 Q2 | -12.27 Million SEK | -59.23% |
| 2016 Q3 | -7.66 Million SEK | 37.58% |
| 2016 Q4 | -18.53 Million SEK | -141.86% |
| 2016 Q1 | -7.7 Million SEK | 30.77% |
| 2016 FY | -46.17 Million SEK | -13.97% |
| 2015 Q3 | -9.86 Million SEK | 5.48% |
| 2015 FY | -40.51 Million SEK | -24.03% |
| 2015 Q4 | -11.13 Million SEK | -12.84% |
| 2015 Q1 | -9.07 Million SEK | 25.88% |
| 2015 Q2 | -10.44 Million SEK | -15.09% |
| 2014 Q4 | -12.24 Million SEK | -95.31% |
| 2014 Q1 | -6.48 Million SEK | -34.84% |
| 2014 Q3 | -6.26 Million SEK | 18.33% |
| 2014 Q2 | -7.67 Million SEK | -18.32% |
| 2014 FY | -32.66 Million SEK | -101.54% |
| 2013 Q2 | -3.54 Million SEK | -39.39% |
| 2013 Q4 | -4.81 Million SEK | 9.4% |
| 2013 FY | -16.2 Million SEK | -111.3% |
| 2013 Q3 | -5.3 Million SEK | -49.72% |
| 2013 Q1 | -2.54 Million SEK | -11.42% |
| 2012 FY | -7.67 Million SEK | -55.95% |
| 2012 Q3 | 1.89 Million SEK | 171.9% |
| 2012 Q2 | -2.62 Million SEK | -46.62% |
| 2012 Q1 | -1.79 Million SEK | 0.0% |
| 2012 Q4 | -2.28 Million SEK | -220.77% |
| 2011 Q2 | -1.33 Million SEK | 0.0% |
| 2011 FY | -4.91 Million SEK | 0.0% |
| 2011 Q3 | -1.5 Million SEK | -12.71% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | -209.71 Thousand SEK | 0.0% |
| 2010 Q3 | -421.65 Thousand SEK | -101.07% |
| 2009 FY | -74.92 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -262.759% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | -25.613% |
| BioGaia AB (publ) | 440.9 Million SEK | 110.901% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | -14.876% |
| Gabather AB (publ) | -9.47 Million SEK | -407.304% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -227.398% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -75.006% |
| Nanexa AB (publ) | -76.62 Million SEK | 37.276% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -241.398% |
| ODI Pharma AB | -1.34 Million SEK | -3482.332% |
| Orexo AB (publ) | -109.5 Million SEK | 56.108% |
| Probi AB (publ) | 11.32 Million SEK | 524.576% |
| Swedencare AB (publ) | 173.2 Million SEK | 127.749% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 101.032% |
| Toleranzia AB | -7.89 Million SEK | -509.074% |
| Vivesto AB | -356.71 Million SEK | 86.527% |